GLP-1受体激素作用导致肝脏乙醇代谢的减少
Frhaan Zahrawi1, Arumugam Suyavaran1, Bubu A Banini1
1The Section of Digestive Diseases, Yale School of Medicine, New Haven, CT, USA.
npj metabolic health and disease
|September 18, 2025
概括
葡萄糖类1受体 (GLP-1R) 激动剂可降低小鼠的酒精摄入量和肝损伤. GLP-1R激素也降低肝脏关键酶,增加血中酒精水平,但保护肝脏毒性.
科学领域:
- 药理学 药理学 是一个学科.
- 肝病学 肝病学是一种肝病学.
- 代谢过程中的代谢.
背景情况:
- 葡萄糖类1受体 (GLP-1R) 激动剂越来越多地使用,但它们对酒精消耗和肝脏代谢的影响尚不清楚.
- 鉴于酒精消费的普遍性和GLP-1R的代谢作用,了解这些相互作用至关重要.
研究的目的:
- 为了研究GLP-1R激素对肝功能和酒精代谢在高乙醇摄入小鼠模型的影响.
- 为了确定GLP-1R激素是否可以减轻乙醇诱导的肝损伤.
主要方法:
- 使用了高乙醇消耗的小鼠模型.
- 服用GLP-1R激动剂和对乙醇摄入量,肝酶表达 (例如Cyp2e1) 和血液乙醇水平的评估影响.
- 评估的肝毒性标志物.
主要成果:
- 在小鼠中,GLP-1R激动剂显著降低了自愿乙醇消耗.
- 乙醇诱导的肝脏代谢酶的上调,包括Cyp2e1,被GLP-1R激素作用减轻.
- GLP-1R激动剂减少了Cyp2e1的表达,而不依赖于乙醇摄入量,导致血液中乙醇水平增加.
- 尽管血中酒精含量升高,但GLP-1R激素对乙醇介导的肝毒性产生保护作用.
结论:
- GLP-1R激动症提供了一种潜在的治疗策略,以减少酒精消耗和相关的肝损伤.
- 该机制涉及调节肝酶活性和潜在的其他途径,导致肝毒性降低,尽管改变了血中酒精的药理动力学.
更多相关视频
08:37Assessment of Glutamine as a Fuel Source for Alveolar Macrophages Exposed to Chronic Ethanol Using an Extracellular Flux Bioanalyzer
Published on: November 15, 2024
754
09:41Measuring the Rate of Lipolysis in Ex Vivo Murine Adipose Tissue and Primary Preadipocytes Differentiated In Vitro
Published on: March 17, 2023
3.6K
相关概念视频
Glucagon-like Receptor Agonists
850
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
850
Dipeptidyl Peptidase 4 Inhibitors
596
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
596
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
526
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
526
GPCRs Regulate Adenylyl Cylase Activity
7.3K
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
7.3K
GPCR Desensitization
7.9K
G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...
7.9K
Oral Hypoglycemic Agents: Glinides
600
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
600
